Ursodiol and Colorectal Cancer or Dysplasia Risk in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Meta-Analysis

Background Patients with primary sclerosing cholangitis (PSC) and colonic inflammatory bowel disease (IBD) demonstrate increased risk of colorectal cancer. Prior studies have yielded conflicting information on the relationship between ursodiol (UDCA) and the risk of colorectal cancer or dysplasia in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive diseases and sciences 2013-11, Vol.58 (11), p.3079-3087
Hauptverfasser:	Hansen, Jonathan D., Kumar, Sonal, Lo, Wai-Kit, Poulsen, David M., Halai, Umme-Aiman, Tater, Kathy C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biochemistry Cancer Cholangitis, Sclerosing - drug therapy Colorectal cancer Colorectal Neoplasms - etiology Comparative analysis Dysplasia Gastroenterology Gastrointestinal diseases Hepatology Humans Inflammatory bowel disease Inflammatory Bowel Diseases - drug therapy Medicine Medicine & Public Health Oncology Oncology, Experimental Pneumoviridae Review Risk Factors Transplant Surgery Ursodeoxycholic Acid - adverse effects Ursodiol
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Patients with primary sclerosing cholangitis (PSC) and colonic inflammatory bowel disease (IBD) demonstrate increased risk of colorectal cancer. Prior studies have yielded conflicting information on the relationship between ursodiol (UDCA) and the risk of colorectal cancer or dysplasia in this group. Aims To examine the impact of UDCA on risk of colorectal cancer or dysplasia in adult PSC and IBD patients. Methods A systematic review and meta-analysis of case–control and cohort studies was performed. Subgroup analysis compared the effects of “low-to-medium” (
ISSN:	0163-2116 1573-2568
DOI:	10.1007/s10620-013-2772-0